Products
Polzastobart Biosimilar Monoclonal Antibody (LILRB2) for Research
Cat No.: GMP-Bios-INN-1339
Anti-LILRB2 therapeutic antibody (Pre-made Polzastobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Polzastobart (development code JTX-8064) is a monoclonal antibody targeting LILRB2. It is developed by Jounce Therapeutics for Cancers in Phase I/II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1339-1mg | 1mg | 3090 |
| GMP-Bios-INN-1339-10mg | 10mg | |
| GMP-Bios-INN-1339-100mg | 100mg | |
| GMP-Bios-INN-1339-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Polzastobart biosimilar, Whole mAb, Anti-LILRB2 Antibody: Anti-ATAD1/LILRB2/CD85d/Leukocyte immunoglobulin-like receptor subfamily B member 2 therapeutic antibody |
| INN Name | Polzastobart |
| Target | LILRB2 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Jounce Therapeutics |
| Conditions Approved | na |
| Conditions Active | Cancers |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
